Coherus Says Tagmokitug Produced Responses In 6 Of 8 First-Line Esophageal Cancer Patients
The experimental antibody, paired with toripalimab and chemotherapy, showed a 75% confirmed response rate in a small interim cohort.
Coherus Oncology, which sells the cancer drug LOQTORZI, said Wednesday that its experimental antibody tagmokitug produced a 75% confirmed response rate — 6 of 8 evaluable patients — in first-line esophageal squamous cell cancer when combined with toripalimab and chemotherapy. The company plans to expand enrollment in both its first-line and second-line esophageal cohorts, according to an 8-K filed Thursday.
Six of eight, then eight of nine
The 75% rate covers patients regardless of PD-L1 status, as of the October 14 data cutoff, and the rate was 100% in PD-L1-positive patients, according to the company's press release. One patient had a confirmed complete response. Ten patients were evaluable for safety, and enrollment continues.
After the cutoff, two more partial responses were confirmed, raising the rate to 89% (8 of 9). The company set the PD-L1-positive result against a US standard-of-care benchmark of 44% to 59% for a PD-1 inhibitor plus chemotherapy, and noted that no PD-1 inhibitor is approved for PD-L1-negative disease in the US.
Dan Feng, an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, said she was "particularly impressed with the front-line response rate."
Second-line results are more modest
In second-line disease, patients were randomized to 300 mg or 700 mg of tagmokitug plus toripalimab. At 700 mg, the confirmed response rate was 16.7% (1 of 6) and the clinical benefit rate was 33.3% (2 of 6). Median progression-free survival was 5.5 months, against a chemotherapy benchmark of about 3.4 months.
Only 8 of 17 safety-evaluable patients were efficacy evaluable, 6 of them on the 700 mg dose.
Other cohorts the company reported:
- Second-line upper gastrointestinal cancers: 23.5% confirmed response (4 of 17 evaluable) at 700 mg.
- Second-line head and neck cancer, HPV-positive: 13.0% (3 of 23).
- Fourth-line-plus colorectal cancer: 5.9% confirmed response and 11.8% clinical benefit.
Safety and the next studies
Among about 120 patients given tagmokitug with toripalimab, immune-related adverse events hit 40% at any grade and 20% at Grade 3 to 5. The company said it found no new safety signals beyond those tied to PD-1 therapy, and no Grade 5 treatment-related events.
Coherus, which also has two mid-stage drug candidates beside its approved PD-1 drug LOQTORZI, plans to study tagmokitug with a T-cell engager in metastatic castration-resistant prostate cancer. Tagmokitug has not been approved by the FDA or any other regulator, and its safety and efficacy have not been established, the company said.
Chief Executive Denny Lanfear said the data give the company "a clear and efficient path" for developing tagmokitug in esophageal cancer.
Sources
- 8-K Filing — Coherus Oncology, Inc. (CHRS) — SEC EDGAR
- Exhibit chrs-ex99d1.htm — Coherus Oncology, Inc. 8-K exhibit — SEC EDGAR
- Coherus releases promising early-stage data on tagmokitug in esophageal cancer | Seeking Alpha — seekingalpha.com
- Coherus Oncology Announces Compelling Tagmokitug Interim — rss.globenewswire.com